HalpinReyessyndromeandmedicationusefull.pdf

Reyes Syndrome and Medication Use Thomas J. Halpin, MD, MPH; Francis J. Holtzhauer, MS; Robert J. Campbell, MS; Lois J. Hall; Adolfo Correa-Villase\l=n~\or,MD, MPH; Richard Lanese, PhD; Janet Rice, PhD; Eugene S. Hurwitz, MD \s=b\ Ninety-seven Reyes syndrome (RS) cases in Ohio children with onsets to assess medication consumption during from December 1978 through March 1980 were studied for medication use the antecedent illness of RS. Ohio resi¬ during their pre-RS illness. They were matched with 156 control subjects for dents having onset of RS between Dec 1, age, race, sex, geographic location, time, and type of illness. Only the use of 1978, and March 31, 1980, were classified aspirin was reported by significantly more cases (97%, 94/97) than controls as cases if they met the following criteria: (71%, 110/156) during the pre-RS matched illness. Using a multiple logistic an acute, noninflammatory encephalopa- model to control for the presence of fever, headache, and sore throat thy as demonstrated by either a CSF level (if available) containing fewer than eight statistically, the difference in aspirin use remained significant. Conversely, WBCs per cubic millimeter or cerebral fewer cases (16%) took medications containing acetaminophen than con- edema without perivascular or meningeal trols (33%). In 87% of the cases receiving aspirin, their maximum daily inflammation associated with (1) micro- dosage